Browsing: Access1

In Dec 2022, the FDA approved BRIUMVI™, a chimeric monoclonal antibody (mAb) labelled for the treatment of RMS

Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022

In Dec 2022, the US Food and Drug Administration (FDA) approved MediWound’s biologic license application (BLA) for anacaulase-bcdb (NexoBrid®)

QDENGA, a live-attenuated, dengue tetravalent vaccine, was approved by Indonesia’s BPOM for the prevention of dengue caused by any serotype.

InnoCare Pharma announced the approval of HIBRUKA (Orelabrutinib) by the HSA of Singapore for the treatment of adult patients with r/r MCL

Consent precedes action, and this is no different for smoking cessation. Asking the right questions as a healthcare professional can…

Disease Burden and Clinical Landscape Hepatorenal syndrome (HRS) is an extreme manifestation of progressive kidney function deterioration in patients with advanced liver…

When it comes to smoking cessation, it’s clear that “the sooner the better”. But how soon is “soon” and what…

After breaking down the evidence which reiterates the importance of smoking cessation after a cardiovascular event (Part 1 and Part…

Smoking cessation is difficult, and it remains so even after life-threatening cardiovascular events. In fact, systematic reviews have reported smoking…